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Abstract
Background: We previously reported that overexpression of Axin downregulates T cell factor-4 (TCF-4)
transcription. However, the mechanism(s) by which Axin downregulates the transcription and expression of TCF-4
is not clear. It has been reported that b-catenin promotes and p53 inhibits TCF-4 transcription, respectively. The
aim of this study was to investigate whether b-catenin and/or p53 is required for Axin-mediated downregulation
of TCF-4.
Results: Axin mutants that lack p53/HIPK2 and/or b-catenin binding domains were expressed in lung cancer cells,
BE1 (mutant p53) and A549 (wild type p53). Expression of Axin or AxinΔp53 downregulates b-catenin and TCF-4,
and knock-down of b-catenin upregulates TCF-4 in BE1 cells. However, expression of AxinΔb-ca into BE1 cells did
not downregulate TCF-4 expression. These results indicate that Axin downregulates TCF-4 transcription via b-
catenin. Although overexpression of wild-type p53 also downregulates TCF-4 in BE1 cells, cotransfection of p53 and
AxinΔb-ca did not downregulate TCF-4 further. These results suggest that Axin does not promote p53-mediated
downregulation of TCF-4. Axin, AxinΔp53, and AxinΔb-ca all downregulated b-catenin and TCF-4 in A549 cells.
Knock-down of p53 upregulated b-catenin and TCF-4, but cotransfection of AxinΔb-ca and p53 siRNA resulted in
downregulation of b-catenin and TCF-4. These results indicate that p53 is not required for Axin-mediated
downregulation of TCF-4. Knock-down or inhibition of GSK-3b prevented Axin-mediated downregulation of TCF-4.
Furthermore, expression of Axin and AxinΔp53, prevented the proliferative and invasive ability of BE1 and A549,
expression of AxinΔb-ca could only prevented the proliferative and invasive ability effectively.
Conclusions: Axin downregulates TCF-4 transcription via b-catenin and independently of p53. Axin may also
inhibits the proliferation and invasion of lung cancer cells via b-catenin and p53.
Background
The wingless/int (Wnt) signaling pathway plays an
important role in tumor cell de-differentiation and pro-
liferation [1]. Evidence indicates that abnormal activa-
tion of the Wnt pathway plays an important role in
tumor progression [2-5]. Activation of the Wnt pathway
requires nuclear accumulation of b-catenin, as well as
association of b-catenin and T cell factor-4 (TCF-4).
TCF-4 induces transcription of target genes, such as c-
myc, cyclin D1, vascular endothelial growth factor (vegf)
and matrix metalloproteinase-7 (mmp-7) [1,6]. Under
normal circumstances, GSK-3b phosphorylates excess b-
catenin facilitating its degradation, resulting in the
dynamic balance between b-catenin generation and
degradation. Mutations resulting in constitutive nuclear
accumulation of b-catenin leads to abnormal Wnt path-
way signaling causing tumor formation [4].
Axin, the product of the mouse Fused (Fu) gene, was
originally identified as an inhibitor of the Wnt-signaling
pathway by virtue of its ability to regulate embryonic
axis formation [7,8]. Axin inhibits the Wnt pathway by
facilitating degradation of b-catenin by serving as a scaf-
folding protein enabling assembly of the APC/Axin/
GSK-3b/b-catenin complex [9]. The Axin antagonist,
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way by binding to Axin directly [10,11], and prevents
inhibition of GSK-3b-dependent phosphorylation of b-
catenin. Most likely this occurs through dissociation of
the APC/Axin/GSK-3b complex [11,12].
Since the Wnt pathway plays an important role in
tumor cell de-differentiation, proliferation and tumor
progression, its primary negative regulator, Axin, is
recognized as an important tumor suppressor [13]. Our
previous study demonstrated that decreased Axin expres-
sion correlates with nuclear localization of b-catenin and
poor differentiation of lung cancer cells. Expression of
Axin not only induced b-catenin degradation, but also
significant downregulationo fT C F - 4m R N Aa n dp r o t e i n
expression. Expression of Axin resulted in decreased pro-
liferation and invasion of lung cancer cells [5]. A
mechanism by which Axin downregulates the transcrip-
tion of TCF-4 has not been described to date. It has been
reported that overexpression of p53 can downregulate
TCF-4 transcription, but p53 do not interact with TCF-4
promoter directly which indicated that some p53 down-
stream genes downregulate TCF-4 transcription [14].
Futhermore, Axin could induce p53-dependent transcrip-
tional activity [15], so it seems likely that Axin might be
able to downregulate TCF-4 mRNA via p53 activation. In
other words, Axin-p53-TCF-4 may act as an alternative
for Axin-b-catenin-TCF-4 when wild type p53 is present.
b-catenin upregulates TCF-4 transcript and protein
expression [16]. Therefore, we propose that Axin may
downregulate TCF-4 expression and TCF-mediated gene
transcription via activation of the p53 pathway and/or
facilitation of b-catenin degradation.
In order to test this hypothesis, we expressed three
mutant Axin plasmids, which inhibit the interaction of
Axin with b-catenin and/or p53 in lung carcinoma cell
lines, BE1 (mutant p53) and A549 (wild type p53) [17].
We hypothesize that Axin expression downregulates
TCF-4 transcription and TCF-mediated gene transcrip-
tion activity in a b-catenin- and/or p53-dependent man-
ner in lung cancer cells.
Results
Axin and AxinΔp53 downregulate TCF-4 expression and
TCF-mediated gene transcription activity in BE1 cells
We first detected the basal expression levels of Axin, b-
catenin, p53, and TCF-4 in BE1 and A549 cells. The
Axin and p53 proteins are barely detectable in BE1 cells.
In addition, p53 is mutant and mRNA levels are low in
BE1 cells [17]. However, Axin and p53 were moderately
expressed in A549 cells. BE1 cells expressed more b-
catenin and TCF-4 than A549 cells, both at the mRNA
and protein levels (P < 0.01, Figure 1).
Axin, AxinΔb-ca (cannot bind b-catenin), AxinΔp53
(cannot bind p53), AxinΔb&P (cannot bind either b-
Figure 1 The mRNA and protein expression levels of Axin and other factors in BE1 and A549 cell line. (A) RT-PCR analysis of BE1 and
A549 cells using the indicated specific primers. (B) Quantitative representation of the RT-PCR analysis. (C) Western blot analyses of BE1 and A549
cells using specific antibodies to the indicated proteins. (D) Quantitative representation of the Western blot anlaysis. * P < 0.05, ** P < 0.01.
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BE1 cells (Figure 2A). Axin protein and mRNA expres-
sion levels were determined to confirm expression (Fig-
ure 2B, Figure 3A and 3B). b-catenin mRNA expression
levels were similar in all groups (P >0 . 0 5 ,F i g u r e3 A
and 3B). However, transfection of Axin and AxinΔp53
results in significant reduction of TCF-4 mRNA levels
(P < 0.01, Figure 3A and 3B). These data demonstrate
that Axin downregulates TCF-4 transcription levels
independently of p53. Levels of TCF-4 mRNA and pro-
tein in AxinΔb-ca or AxinΔb&P expressing cells was
similar to the control cells (P > 0.05, Figure 3A and 3B),
suggesting that b-catenin is required for Axin-mediated
downregulation of TCF-4 transcription.
Western blot analysis confirmed that expression of
Axin and AxinΔp53 resulted in a significant reduction
in TCF-4 and b-catenin protein levels (P <0 . 0 1 ,F i g u r e
3C and 3D). These results suggest that Axin downregu-
lates the expression of TCF-4 at the mRNA level and b-
catenin at the protein level in a p53-independent, b-
catenin-dependent manner in BE1 cells.
Dual-luciferase assay results show that expression of
Axin and AxinΔp53 significantly downregulate TCF-4
promoter activity and TCF-mediated gene transcription
activity (P < 0.01, Figure 3E and 3F). In contrast, no sig-
nificant difference was detected in AxinΔb-ca and
AxinΔb&P expressing cells when compared with
controls (P > 0.05). These results show that Axin inhi-
bits the Wnt signaling pathway by downregulating b-
catenin and TCF-4 expression levels in a p53-indepen-
dent, b-catenin-dependent manner.
Axin, AxinΔp53, and AxinΔb-ca downregulate TCF-4
expression and TCF-mediated gene transcription activity
in A549 cells
To further delineate the mechanism by which Axin-
mediates downregulation of TCF-4 transcription, we
determined whether expression of wild type and/or
mutant forms of Axin downregulate TCF-4 in cells with
wild-type p53. A549 cells were transfected with Axin,
AxinΔb-ca, AxinΔp53 and AxinΔb&P. Axin and Axin
mutant mRNA expression levels were determined 48 h
post-transfection to confirm expression (P < 0.01, Figure
4A and 4B). Protein expression was also confirmed
(data not shown). There was no significant change in b-
catenin and p53 mRNA levels in any group (P > 0.05).
However, TCF-4 mRNA levels were significantly lower
in Axin, AxinΔb-ca and AxinΔp53 expressing cells com-
pared to controls (P < 0.01, Figure 4A and 4B). It
appears that Axin downregulates TCF-4 transcription
via either b-catenin and p53 in A549 cells, as AxinΔb&P
expression does not result in downregulation of TCF-4
mRNA expression. In addition, we found that downre-
gulation of TCF-4 mRNA in Axin and AxinΔp53
expressing cells was more significant than in AxinΔb-ca
Figure 2 The composition and expression of Axin mutants. (A) Schematic representation of the mutants of the Axin mutants used in this
study. The binding sites for HIPK2, b-catenin and p53 are indicated. (B) BE1 cells were transfected with the indicated EGFP-tagged Axin
construct. Total cell lysates were resolved by SDS-PAGE and Western blot analysis was performed using anti-EGFP antibody to detect the
expression of the different Axin mutants.
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the b-catenin pathway is the primary mechanism by
which Axin downregulates TCF-4 transcription.
Expression of Axin and AxinΔp 5 3i nA 5 4 9c e l l s
results in significant downregulation of b-catenin and
TCF-4 protein levels (P < 0.01, Figure 4C and 4D), simi-
lar to BE1 cells. In contrast to the results with BE1 cells,
expression of AxinΔb-ca also downregulated b-catenin
and TCF-4 protein (P < 0.05), but the effect was signifi-
cantly weaker than with expression of Axin and
AxinΔp53 (P < 0.05). Expression of a mutant that can-
not bind b-catenin or p53, AxinΔb&P, resulted in no
downregulation of TCF-4 mRNA or protein expression.
Dual-luciferase assay showed that expression of Axin,
AxinΔp53 and AxinΔb-ca in A549 cells leads to signifi-
cant downregulation of TCF-4 promoter activity and
TCF-mediated gene transcription (P < 0.01, Figure 4E
and 4F). In contrast to BE1 cells, transfection of
AxinΔb-ca also downregulates TCF-4 promoter activity
and TCF-mediated transcription (P < 0.05), but the
effect was significantly weaker than with transfection of
Axin or AxinΔp53 (P < 0.01).
LiCl treatment and GSK-3b knock-down prevents Axin-
mediated downregulation of TCF-4 in BE1 and A549 cells
To further investigate whether Axin downregulates
TCF-4 via b-catenin, BE1 cells were transfected with
wild-type and mutant Axin constructs, and, subse-
quently, treated with the GSK-3b inhibitor, LiCl. Expres-
sion levels of b-catenin and p53 mRNA did not change
after treatment with LiCl for any transfection group (P
> 0.05, Figure 5A and 5B). However, TCF-4 mRNA
levels were not reduced in Axin and AxinΔp53 expres-
sing cells after LiCl treatment compared to controls (P
> 0.05).
Western blot analysis shows that LiCl treatment of
Axin and AxinΔp53 expressing BE1 cells prevents
Figure 3 The effect of transfecting various Axin plasmids into BE1 cells. Axin, AxinΔb-ca, AxinΔp53 and AxinΔb&P were transfected into BE1
cells. (A) Forty-eight hours after transfection total RNA was isolated and RT-PCR analysis was performed using the indicated primers. (B)
Quantification of mRNA expression after transfection. (C) Proteins expression of BE1 cells 48 h after transfection using the indicated antibodies.
(D) Quantification of protein expression 48 h after transfection of BE1 cells with (E) the TCF-4 promoter construct and (F) TCF reporter construct.
* P < 0.05, ** P < 0.01.
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0.05, Figure 5C and 5D). These data suggest that TCF-4
mRNA expression levels are correlated with b-catenin
protein expression levels in BE1 cells. Dual-luciferase
assay demonstrates that LiCl treatment of Axin and
AxinΔp53 expressing cells also inhibits downregulation
TCF-4 promoter activity and TCF-mediated gene tran-
scription activity (P > 0.05, Figure 5E and 5F). Collec-
tively, these results suggest that upregulation of b-
catenin and TCF-4 is required for increased TCF-4 pro-
moter activity and TCF-mediated gene transcription
activity. Similar results were obtained in Axin, AxinΔb-
ca or AxinΔp53 expressing A549 cells with LiCl treat-
ment. Axin, AxinΔb-ca or AxinΔp53-mediated reduc-
tion of TCF-4 mRNA and protein expression, and b-
catenin protein, was inhibited with LiCl treatment. LiCl
treatment did not affect b-catenin and p53 mRNA
expresssion levels (P > 0.05, Figure 6). It was noted that
the b-catenin and TCF-4 protein levels were inversely
regulated in AxinΔb-ca expressing A549 cells. There-
fore, it seems that regardless of p53 status, TCF-4
mRNA levels were correlated with b-catenin protein
levels.
We also found that LiCl treatment inhibited the
downregulation of TCF-4 promoter activity and TCF-
mediated gene transcription in Axin, AxinΔb-ca and
AxinΔp53 expressing A549 cells (P > 0.05, Figure 6E
and 6F). Therefore, these data demonstrate that Axin
requires GSK-3b to inihibit TCF-4 and suggests that
this mechanism is likely b-catenin-dependent.
To confirm the LiCl treatment results, siRNA was
used to knock-down GSK-3b to prevent b-catenin
downregulation. Results were similar with LiCl treat-
ment. Knock-down of GSK-3b inhibited Axin-mediated
Figure 4 The effect of transfecting various Axin plasmids into A549 cells. Axin, AxinΔb-ca, AxinΔp53 and AxinΔb&P were transfected into
A549 cells. (A) Forty-eight hours after transfection total RNA was isolated and RT-PCR analysis was performed using the indicated primers. (B)
Quantification of mRNA expression after transfection. (C) Protein expression of A549 cells 48 h after transfection using the indicated antibodies.
(D) Quantification of protein expression 48 h after transfection of A549 cells with (E) the TCF-4 promoter construct and (F) TCF reporter
construct. * P < 0.05, ** P < 0.01.
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of TCF-4 in both BE1 and A549 cells (P > 0.05, Figure
7).
Wild-type p53 downregulates TCF-4 mRNA and protein,
and is not enhanced by Axin
To investigate whether AxinΔb-ca downregulates TCF-4
transcription via p53, we transfected wild-type p53 into
BE1 cells. Overexpression of p53 downregulates TCF-4
mRNA and protein, but cotransfection of AxinΔb-ca
and p53 did not downregulate TCF-4 further (Figure
8A-D). These results suggest that Axin cannot enhance
p53-mediated downregulation of TCF-4, that Axin does
not downregulate TCF-4 via p53, and that the Axin-
p53-TCF-4 pathway is not functional in BE1 cells.
Furthermore, we downregulated p53 expression in
A549 cells by siRNA. Results show that TCF-4 mRNA
and protein were significantly upregulated after siRNA
treatment, proving that wild-type p53 is able to downre-
gulate TCF-4 (P < 0.01, Figure 8E-H). We next trans-
fected AxinΔb-ca into A549 cells in which p53 had
been knocked-down, and found that AxinΔb-ca further
downregulate TCF-4 transcription, suggesting that Axin
downregulates TCF-4 in a p53-independent manner.
To further investigate whether b-catenin expression
positively correlates with TCF-4 expression, we
knocked-down b-catenin in BE1 and A549 cells by
siRNA. Loss of b-catenin resulted in downregulation of
TCF-4 in both cell lines (P < 0.01, Figure 8). As we have
Figure 5 The effect of LiCl treatment on BE1 cells transfected with different Axin plasmids. Axin, AxinΔb-ca, AxinΔp53 and AxinΔb&P were
transfected into BE1 cells. Twenty-four hours post-transfection, cells were treated with LiCl (20 mM). (A) Forty-eight hours after transfection total
RNA and RT-PCR analysis was performed using the indicated primers. (B) Quantification of mRNA expression after transfection. (C) Protein
expression in BE1 cells 48 h after transfection using the indicated antibodies. (D) Quantification of protein expression 48 h after transfection with
(E) the TCF-4 promoter construct and (F) TCF reporter construct. * P < 0.05, ** P < 0.01.
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a p53-independent manner. Transfection of AxinΔb-ca
into A549 cells did not result in further downregulation
of TCF-4, suggesting that Axin downregulates TCF-4
via b-catenin, not p53.
Axin reduces proliferation and invasion of lung cancer
cells via b-catenin and p53
To determine if Axin affects proliferation, cell growth
assays were performed using Axin, AxinΔb-ca,
AxinΔp53 or AxinΔb&P expressing BE1 and A549 cells.
No marked difference was observed in BE1 cells expres-
sing Axin and Axin mutant 24 h after transfection.
However, 48 h post-transfection we found that expres-
sion of Axin and AxinΔp53 significantly decreased
cellular proliferation of BE1 cells (P < 0.01, Figure 9A).
Expression of AxinΔb-ca only slightly decreased the
growth of BE1 cells (P < 0.05). In A549 cells, expression
of Axin, AxinΔp53 and AxinΔb-ca significantly
decreased proliferation at 48 h post-transfection (P <
0.01, Figure 9B). However, expression of Axin inhibited
A549 cell proliferation more strongly than expression of
AxinΔp53 or AxinΔb-ca (P <0 . 0 1 ) .T h e s er e s u l t ss u g -
gest that Axin inhibits proliferation of lung cancer cells
via both the b-catenin and p53 pathways.
In order to determine if Axin plays a role in invasion,
transwell assays were performed using Axin, AxinΔb-ca,
AxinΔp53 or AxinΔb&P expressing BE1 and A549 cells.
In transwell assays, invasion potential is measured by
Figure 6 The effect of LiCl treatment on A549 cells transfected with different Axin plasmids.A x i n ,A x i n Δb-ca, AxinΔp53 and AxinΔb&P
were transfected into A549 cells. Twenty-four hours post-transfection, cells were treated with LiCl (20 mM). (A) Forty-eight hours after
transfection total RNA and RT-PCR analysis was performed using the indicated primers. (B) Quantification of mRNA expression after transfection.
(C) Protein expression in A549 cells 48 h after transfection using the indicated antibodies. (D) Quantification of protein expression 48 h after
transfection with (E) the TCF-4 promoter construct and (F) TCF reporter construct. * P < 0.05, ** P < 0.01.
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layer and adhere to the transwell filter. Expression of
Axin and AxinΔp53 in BE1 cells significantly decreased
invasion compared with control groups by 48 h after
transfection (P < 0.01, Figure 10A and 10B). Surpris-
ingly, expression of AxinΔb-ca also reduced the number
of invasive cells (P < 0.05), but the effect was much
weaker than with expression of Axin or AxinΔp53 (P <
0.01). These results suggest that the primary mechanism
by which Axin reduces the invasion ability of lung can-
cer cells is through inhibition of b-catenin. Interestingly,
in A549 cells, expression of AxinΔb-ca decreased
invasion as effectively as expression of AxinΔp53 (P <
0.01, Figure 10C and 10D), yet expression of Axin is the
most potent inhibitor of invasion ability (P < 0.01).
These results suggest that Axin decreases lung cancer
cell invasion ability via the b-catenin and p53 pathways.
Discussion
We have previously reported that there is a significant
r e d u c t i o ni nA x i ne x p r e s s ion and increased nuclear
accumulation of b-catenin in human lung cancer speci-
mens [18]. Axin decreased expression of TCF-4, but
whether b-catenin is plats a role in this process has not
Figure 7 The effect of GSK-3b siRNA treatment on BE1 cells and A549 cells transfected with different Axin plasmids. Axin, AxinΔb-ca,
AxinΔP53 and AxinΔb&P were cotransfected with GSK-3? siRNA into BE1 (A-D) and A549 (E-H) cells. (A&E) Forty-eight hours after transfection
total RNA and RT-PCR analysis was performed using the indicated primers. (B&F) Quantification of mRNA expression after cotransfection. (C&G)
Western blot analysis of BE1 and A549 cells 48 h after transfection using the indicated antibodies. (D&H) Quantification of protein expression
after transfection. * P < 0.05, ** P < 0.01.
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with homeodomain-interacting protein kinase-2 (HIPK2)
and p53, inducing p53 activity and facilitating p53-
mediated transcription activity [15]. Rother, et al.f o u n d
that some p53 target genes might downregulate TCF-4
transcription [14], so it seems likely Axin can downregu-
late TCF-4 transcription via p53. Others have reported
that expression of b-catenin in endometrial cancer cells
upregulates the expression of TCF-4 [16] and that Axin
faciltates the degradation of b-catenin [9]. Therefore, it
is also possible that Axin may downregulate TCF-4
transcription via b-catenin. But whether Axin downre-
gulates TCF-4 via the p53 and/or b-catenin pathway
and whether one pathway is preferred has not been
determined. It has been shown by many in vitro studies
that Axin interacts with GSK-3b, APC, and b-catenin to
form a degradation complex. Furthermore, mutant Axin
which cannot interact with GSK-3b,A P C ,o rb-catenin
cannot induce b-catenin degradation [19-25]. Therefore,
we expressed wild type Axin and mutants lacking p53
and/or b-catenin binding domains in lung cancer cell
lines expressing wild type (A549) or mutant (BE1) p53
Figure 8 Axin-mediated downregulation of TCF-4 is p53-independent. BE1 cells were transfected with wild-type p53 or b-catenin siRNA,
respectively, cotransfection of wild-type p53 and AxinΔb-ca was also performed in BE1 cells. A549 cells were transfected with p53 siRNA or b-
catenin siRNA, respectively, and cotransfection of b-catenin siRNA and AxinΔb-ca, p53 siRNA and AxinΔb-ca were also performed in A549 cells.
(A&E) Forty-eight hours after transfection total RNA and RT-PCR analysis was performed using the indicated primers. EGFP and control siRNA
served as control groups. (B&F) Quantification of mRNA expression after transfection. (C&G) Western blot analysis was performed 48 h after
transfection using the indicated antibodies. (D&H) Quantification of protein expression after transfection * P < 0.05, ** P < 0.01.
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lates TCF-4 expression.
Our results suggest that regardless of the status of the
p53 pathway Axin is able to downregulate b-catenin
protein, but not mRNA expression levels. In addition,
Axin also downregulates TCF-4 expression levels and
TCF-mediated gene transcription in a p53-independent
manner. Furthermore, our results demonstrate that
Axin-mediated downregulation of TCF-4 and TCF-
mediated gene transcription is b-catenin dependent.
W eh a v es h o w nt h a ta nA x i nc o n s t r u c tt h a tc a n n o t
bind b-catenin, AxinΔb-ca, downregulates b-catenin and
TCF-4. It has been previously reported that AxinΔb-ca
may still be effective in facilitating b-catenin destruction
due to complementing interactions with other members
of this complex [26]. However, we feel that this is not
likely occurring in our experiments, because transfection
of AxinΔb-ca did not result in downregulation of TCF-
4. Therefore, differences between our and previously
published results might be caused by cell-type and/or
species specific differences. The different results
obtained from expression of AxinΔb-ca in BE1 and
A549 cells is likely caused by different endogenous Axin
expression levels. Axin expression was barely detectable
in BE1 cells, but moderate in A549 cells. It has been
reported that dimerization of Axin is very important for
its function [27]. So, it is possible that AxinΔb-ca could
form dimers with abundan tw i l d - t y p eA x i ni nA 5 4 9
cells, making wild-type Axin more stable and effective,
resulting in b-catenin degradation and TCF-4 downre-
gulation in an Axin-b-catenin-TCF-4 manner. BE1 cells
lack wild-type Axin, so AxinΔb-ca could not function in
the same manner. It has also been reported that Axin
f o r m sd i m e r sb yt h eD I Xd o m a i n[ 2 8 ] ,a n dA x i n Δb-ca
contains this domain. However, AxinΔb&P also contains
the DIX domain, but transfection of AxinΔb&P did not
result in downregulation of b-catenin and TCF-4.
Furthermore, Lin, et al. found that Axin dimerization
through the DIX domain is weak, and AxinΔb&P Shear-
ing three long parts that might influence the ability of
AxinΔb&P forming dimmers with wild type Axin, so
transfection of AxinΔb&P did not downregulate b-cate-
nin and TCF-4 in A549.
We treated A549 by LiCl to block the degradation of
b-catenin, we found that in A549 cells after LiCl treat-
ment, the expression levels of b-catenin and TCF-4 as
well as the TCF-4 promoter and TCF-mediated gene
transcription activity were significantly higher than
those in nontreated cells, but this did not happen in
BE1 cells. We reasoned that this result had to do with
differences in expression levels of endogenous Axin.
The expression of endogenous Axin is relatively high in
the A549 cell line, but relatively low in the BE1 cell line.
Axin could provide a platform for GSK-3b facilitation of
b-catenin degradation, thereby keeping b-catenin
expression at a relatively low level. b-catenin expression
was upregulated when LiCl blocked GSK-3b activity in
A549 cells. Meanwhile, GSK-3b may not have been able
to facilitate b-catenin degradation in BE1 cells because
they lack the Axin platform. Likewise, LiCl treatment
m a ya l s ob eu n a b l et ou p r e g u l a t eb-catenin expression
further in BE1 cells by blocking GSK-3b activity. In
addition, using GSK-3b siRNA could upregulate b-cate-
nin and TCF-4 in A549 but not in BE1, which proved
our hypothesis.
We previously reported that overexpression of Axin
inhibits proliferative and invasive ability of lung cancer
cells [18]. In this study, we found that transfected Axin
Figure 9 Transfecting various Axin plasmids influences the proliferative ability of BE1 and A549 cells. Cells were transfected with Axin,
AxinΔb-ca, AxinΔP53 and AxinΔb&P and plated into wells 12 h post-transfection. MTT assay was performed every day for four days. Growth
curves were generated for BE1 cells (A) and A549 cells (B).
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sive ability of BE1 and A549 cell lines significantly, but
transfection of AxinΔb-ca could only downregulate the
proliferation and invasion of A549 cell significantly.
Additionally, expression of AxinΔb-ca also downre-
gualtes proliferative and invasive ability significantly as
powerful as AxinΔp53 in A549, which differ from their
effects on TCF-4 transcription downregulation. This
result indicated that Axin might inhibit proliferation
and invasion via both b-catenin and wild type p53 path-
way. This result indicated that Axin might inhibit prolif-
eration and invasion via both b-catenin and wild type
p53 pathway.
Conclusions
In this study, we employed two lung cancer cell lines,
BE1 (mutant p53) and A549 (wild-type p53) to delineate
the mechanism by which Axin downregulates TCF-4
expression. We demonstrate that Axin downregulates
TCF-4 transcription and TCF-mediated gene transcrip-
tion in a b-catenin-dependent manner in lung cancer
cells. We also show wild-type p53 induces of downregu-
lation of TCF-4 transcription in lung cancer cells, and
Axin coexpression does not lead to further inhibition.
Axin downregulates TCF-4 transcription via the Axin-b-
catenin-TCF-4 pathway. Axin might inhibit proliferation
and invasion via both the b-catenin and p53 pathways. At
the present time, there is much interest focused on the
Wnt signaling pathway in cancer [29], yet research in this
area has yielded little clinical impact [30]. Recently, we
found that prognosis of patients with high expression of
Axin was better than those with low expression, elevated
Axin expression following X-ray exposure is a reliable
indicator for determining the radiosensitivity of NSCLC
[31]. Together, our study suggests that induction of Axin
Figure 10 Expression of various Axin constructs decreases the invasive ability of BE1 and A549 cells. Cells were seeded on the upper
chamber (5 × 10
4 cells/well) 24 h after transfection and incubated for 48 h. (A&C) A representative microscope field of filters under the Matrigel
from BE1 and A549, respectively. (B&D) Quantification of the number of migrated BE1 and A549 cells, respectively. * P < 0.05, ** P < 0.01.
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treatment for lung cancer patients.
Methods
Plasmid construction
Mouse Axin cDNA (2.6 kb) was kindly provided by pro-
fessor Perrella [32], and sequence verification was per-
formed (TaKaRa Biotechnology Co., Japan). The Axin
gene was inserted into the SacII and SmaI sites of the
pEGFP-N1 vector (Clontech, Mountain View, CA),
pEGFP-Axin, then used to construct Axin mutant vec-
tors, pEGFP-AxinΔb-ca (b-catenin binding site aa 433-
501 mutation), pEGFP-AxinΔp53 (HIPK2 binding site
aa 678-753 and p53 binding site aa 209-338 mutation),
pEGFP-AxinΔb&P (b-catenin, HIPK2 and p53 binding
sites mutation). Deletion mutations were performed to
construct these Axin mutant vectors (Figure 1A).
p53, b-catenin, GSK-3b siRNA sequences were pur-
chased from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA). TCF-4 reporter gene construct, pGL-[1306]TCF4-
Luc, were kindly provided by Dr. Kurt Engeland [33].
The TCF-mediated reporter gene construct, the wild
type p53 plasmid, pGL3-OT (TopFlash) and pGL3-OF
(FopFlash), were kindly provided by Dr. Bert Vogelstein
[34].
Cell Culture and Transfection
The BE1 cell line was a gift from Dr. Jie Zheng (College
of Medicine, Beijing University, China). A549 cells were
purchased from ATCC. Cells were cultured in RPMI
1640 medium (GIBCO Inc., Carlsbad, CA) and DMEM
medium (GIBCO Inc.), respectively, with 10% fetal calf
serum (GIBCO Inc.) at 37°C, 5% CO2.
BE1 and A549 cell were plated in 60 mm dishes. At
approximately 90% confluency, cells were cultured for 3
h in medium without serum, and then transfected using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) with
empty vector or either mutant or wild type Axin accord-
ing to the manufacturer’sp r o t o c o l .G S K - 3 b inhibitor,
LiCl(20 mM) was added 24 h post-transfection [16].
RT-PCR assay
Total RNA was extracted from samples using Trizol®
Reagent (Invitrogen, Carlsbad, CA). RT-PCR analysis
was performed using primers specific for Axin, b-cate-
nin, p53 and TCF-4 using a TaKaRa RNA PCR Kit
(AMV) Ver. 3.0 (Takara, Dalian, China) according to the
manufacturer’sp r o t o c o l .b-Actin served as an internal
control. Primer sequences used are listed in Table 1.
After resolving the products by agarose electrophoresis,
the gel was stained with ethidium bromide and analyzed
using a BioImaging system to visualize bands (UVP,
Upland, CA). Relative band intensities were determined
using NIH image software.
Western blot assay
Cell pellets were collected and total protein was
extracted using RIPA buffer + PMSF (Sigma-Aldrich,
Inc., St. Louis, MO). Protein was quantified by staining
with Coomassie Brilliant Blue G-250. Protein lysate was
resolved by SDS-PAGE and subsequently transferred to
PVDF membrane (Sigma-Aldrich, Inc.). Membrane was
blocked in 3% fetal calf serum, followed by incubation
with GFP antibody (1:200, Santa Cruz Biotechnology
Inc, Santa Cruz, CA), Axin antibody (1:200, Santa Cruz
Biotechnology Inc, Santa Cruz, CA), b-catenin antibody
(1:800, BD Biosciences, San Jose, CA), mutant p53 anti-
body (DO-7, 1:200, Thermo Fisher Scientific Inc, Fre-
m o n t ,C A ) ,w i l dt y p ep 5 3a n t i b o d y( A b - 5 ,1 : 2 0 0 ,
Calbiochem-Novabiochem Inc., La Jolla, CA), TCF-4
antibody (1:800, Millipore, USA), or b-actin antibody
(1:200, Santa Cruz Biotechnology Inc.) overnight at 4°C.
Membranes were washed and incubated with secondary
antibody (Santa Cruz Biotechnology Inc.) at 37°C for 2
h. Membranes were washed and ECL reagent applied
Table 1 Primer Sequences
name primer sequence product length temperature cycles
Axin* Forward:5’-ACCGAAAGTACATTCTTGATAAC-3’ 452 52 30
Reverse:5’-TCCATACCTGAACTCTCTGC-3’
Axin** Forward:5’-TCCACCACCATGTTCACC-3’ 243 bp 57.6°C 30
Reverse:5’-CAGCATTGGCATTCTTCC-3’
b-catenin Forward:5’-GCCAAGTGGGTGGTATAGAG-3’ 330 bp 49°C 30
Reverse:5’-GCTGGGTATCCTGATGTGC-3’
p53 Forward:5’-TCAGTCTACCTCCCGCCATA-3’ 322 bp 58°C 30
Reverse:5’ TTACATCTCCCAAACATCCCT 3’
TCF-4 Forward:5’-CGAGGGTGATGAGAACCTGC-3’ 444 bp 52°C 30
Reverse:5’-CCCATGTGATTCGATGCGT-3’
b-actin Forward:5’-AGAGCTACGAGCTGCCTGAC3’ 308 bp 55°C 30
Reverse:5’-AGTACTTGCGCTCAGGAGGA-3’
* This primer specifically detects endogenous human Axin mRNA.
**This primer specifically detects exogenous mouse Axin mRNA, but not endogenous human Axin mRNA.
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visualized by autoradiography (Kodak film KODAK,
Japan). Protein bands were quantified by BioImaging
Systems (UVP) as a ratio to b-actin expression in each
sample.
Dual-luciferase assay
Cells were co-transfected with TCF-4 promoter reporter
gene plasmid, pGL-[1306]TCF4-Luc, or TCF-mediated
transcription reporter gene plasmid, pGL3-OT and
pGL3-OF, using Lipofectamine 2000 according to the
manufacturer’s instruction. Cells were plated in 24-well
plates 24 h prior to transfection. After incubation for 48
h at 37°C, reporter gene expression was detected by the
Dual-Luciferase Assay System (Promega, Madison, WI).
TCF-mediated gene transcription activity was deter-
mined by the ratio of pGL3-OT to pGL3-OF luciferase
activity, which was normalized to Renilla luciferase
activity from the control plasmid, pRL-TK. TCF-4 pro-
moter activity was determined by the value of pGL-
[1306]TCF4-Luc luciferase activity, which was also nor-
malized by Renilla luciferase activity of pRL-TK. The
final relative luciferase activity was determined as the
ratio of activity in cells transfected with Axin constructs
to the EGFP transfected control cells.
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide (MTT) Assay
Cells were seeded in 96-well plates (1 × 10
4 cells/well)
12 h after transfection. Cells were counted each day
for four days after transfection using the MTT method
(MTT detection kit, Keygene, Nanjing, China) accord-
ing to the manufacturer’s instructions. The absorbance,
which is directly proportional to the number of living
cells in culture, was measured at 570 nm using a
microplate reader (Model 550, Bio-Rad, Hercules, CA).
Matrigel Invasive Assay
Cell invasive ability was examined using a 24-well trans-
well® with 8 μm pore polycarbonate membrane inserts
(Corning Inc., Lowell, MA) according to the manufac-
turer’s protocol. Matrigel (100 μg/ml) was applied to
the upper surface of the membranes. Cells were seeded
on the upper chamber (5 × 10
4 cells/well) 24 h after
transfection and incubated for 48 h. Cells that had
invaded the surface of the membrane were fixed with
methanol and stained with hematoxylin. Ten random
high magnification microscope fields per filter were
counted.
Statistical Analysis
Statistics for the experimental data were performed by
SPSS 13.0. Experiments were performed in triplicate,
and the mean was calculated to be the final result. The
Mann-Whitney U test was used to analyze the results of
RT-PCR, Western blot, MTT, Matrigel invasive assay,
TCF-4 promoter activity and TCF-mediated gene tran-
scription activity. P< 0.05 were considered statistically
significant differences, P< 0.01 were considered highly
statistically significant differences.
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